Zelira Therapeutics Limited
ZLDAF
$0.2992
$0.041616.15%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 200.00 | 200.00 | 13.30K | 13.20K | 17.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 200.00 | 200.00 | 13.30K | 13.20K | 17.80K |
| Cost of Revenue | 900.00 | 900.00 | 66.80K | 66.70K | 41.10K |
| Gross Profit | -700.00 | -700.00 | -53.60K | -53.50K | -23.20K |
| SG&A Expenses | -64.50K | -66.30K | 252.20K | 251.70K | 521.40K |
| Depreciation & Amortization | 48.90K | 50.30K | 66.70K | 66.60K | 90.10K |
| Other Operating Expenses | 31.20K | 32.10K | -7.10K | -7.00K | 10.10K |
| Total Operating Expenses | 476.50K | 490.00K | 894.90K | 893.10K | 1.07M |
| Operating Income | -476.30K | -489.70K | -881.70K | -879.80K | -1.05M |
| Income Before Tax | -809.40K | -832.30K | -796.40K | -794.80K | -11.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -809.40K | -832.30K | -796.40K | -794.80K | -11.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 24.00K | 24.70K | -5.60K | -5.60K | 61.20K |
| Net Income | -785.40K | -807.60K | -802.00K | -800.40K | -11.12M |
| EBIT | -476.30K | -489.70K | -881.70K | -879.80K | -1.05M |
| EBITDA | -447.50K | -460.20K | -835.40K | -833.70K | -959.90K |
| EPS Basic | -0.07 | -0.07 | -0.07 | -0.07 | -0.98 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.04 | -0.04 | -0.06 |
| EPS Diluted | -0.07 | -0.07 | -0.07 | -0.07 | -0.98 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.04 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M |
| Average Diluted Shares Outstanding | 11.35M | 11.35M | 11.35M | 11.35M | 11.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |